Gallmetzer HealthCare (GHC) offers multiple avenues for organic growth and margin expansion.
Efter ett par tuffa år med kraftiga nedskärningar från regionerna syns nu tecken på en vändning för ...
This morning, GomSpace announced a new partnership with an undisclosed European space company, where...
Redeye updates its base case on Oncopeptides' announcement that CHMP has adopted a positive opinion ...
Swissnet has published its FY25 report, two months past the statutory deadline and materially below ...
Redeye initiates coverage of AddLife, a specialized European serial acquirer operating across Medtec...
* We add the recent equity raise to our numbers... * .
BeammWave's third-generation RF chip is alive. The bring-up removes the largest technical risk in th...
Redeye comments briefly on Sleep Cycle’s announcement that it will streamline the organisation and s...
Mendus has initiated the Phase Ib DIVA trial, marking the first clinical evaluation of vididencel in...
* We hosted CEO Johan Larsson * Strong market conditions while NYAB continues to gain share * 20% ea...
Mendus has initiated the Phase Ib DIVA trial, evaluating vididencel in combination with venetoclax a...
Redeye strengthens its positive view on Vertiseit following Visual Art’s global framework agreement ...
As in Q2/26, we expect a changed business mix to drive strong organic sales growth while putting som...
Endomines reported new drilling results today which, in our view, continue the previous pattern of m...
Redeye comments on ExpreS2ion’s announcement that it has secured a guarantee undertaking of approxim...
bet-at-home.com is to report its Q2 26 figures on 21 September.
Following Friday's guidance cut, MHP released its H1 report yesterday, confirming the picture.
Mendus is drawing SEK16.5m under the second tranche of its SEK50m loan facility with Fenja Capital, ...
Relais announced today that Joonas Mäkipeska has been appointed as a new CFO, starting no later than...
